S-Equol enhances osteoblastic bone formation and prevents bone loss through OPG/RANKL via the PI3K/Akt pathway in streptozotocin-induced diabetic rats

S-Equol enhances osteoblastic bone formation and prevents bone loss through OPG/RANKL via the PI3K/Akt pathway in streptozotocin-induced diabetic rats

BackgroundThis study aimed to explore whether S-Equol delays diabetes-induced osteoporosis and the molecular mechanisms underlying its therapeutic effects.Materials and methodsThirty-five male Sprague–Dawley rats were randomized into five groups. The diabetic osteoporosis (DOP) group and three S-Equ...

Full description

Bibliographic Details
Main Authors: Zhe Xu, Jing Xu, Shuo Li, Hanqiang Cui, Guiming Zhang, Xiangmin Ni, Jian Wang
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-10-01
Series:Frontiers in Nutrition
Subjects:
diabetic osteoporosis (DOP)
S-Equol
estrogen receptor β (ERβ)
AKT
osteoprotegerin (OPG)
receptor activator of nuclear factor kappa-B ligand (RANKL)
Online Access:https://www.frontiersin.org/articles/10.3389/fnut.2022.986192/full

Internet

https://www.frontiersin.org/articles/10.3389/fnut.2022.986192/full

Similar Items